Marra Camillo, Beccia Flavia, Caffarra Paolo, L'Abbate Federica, Agosta Federica, Benussi Alberto, Bonanni Laura, Bruni Amalia C, Bruno Giuseppe, Cappa Stefano F, Cerami Chiara, Di Lorenzo Francesco, Ferrarese Carlo, Galimberti Daniela, Guarnieri Biancamaria, Mariani Claudio, Nacmias Benedetta, Pantoni Leonardo, Piccoli Tommaso, Perani Daniela, Rainero Innocenzo, Tagliavini Fabrizio, Venneri Annalena, Boccia Stefania, Cagnin Annachiara, Calabrò Giovanna Elisa, Bozzali Marco
Department of Psychology, Catholic University of the Sacred Heart, Milan, Italy.
Memory Clinic, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Neurol Sci. 2025 Apr 16. doi: 10.1007/s10072-025-08143-5.
This national expert-based Delphi-consensus aims at formulating recommendations on the management of dementia care in Italy. This effort seems important and timely given in light of a new scenario arising from a new biological definition of Alzheimer's disease (AD) and the availability of disease-modifying treatments (DMTs).
the Steering Committee of the Italian Neurological Society for dementia (SINdem) created appropriate statements. Invited SINdem experts were requested to vote on the statements according to a modified three-round Delphi method. Only those statements reaching Grade A (full agreement ≥ 75%) or B (overall agreement ≥ 80% and full disagreement < 5%) were included in the final document. Round answers' consistency was graded using the Cohen's k and within-class correlation coefficient.
Forty-six experts voted on 20 statements, which focused on the following aspects: i) organization of care services from early diagnosis to the management of advanced clinical stages; ii) access to biomarkers for a biological diagnosis of AD; iii) requirements necessary for the administration of DMTs; iv) main actors and pathways for the management of patients suffering from cognitive disorders. At the end of the process, 4 statements (20%) received a Grade A consensus, while 16 (80%) reached a Grade B consensus. Although the responses reflect heterogeneity among Italian regions, there was a fair degree of consistency for all statements.
The high strength of this expert-based Delphi-consensus may offer guidance for improving the patient's journey of individuals with cognitive decline from a biological diagnosis to DMTs administration and may possibly offer hints to the Health Systems on dementia.
这项基于全国专家的德尔菲共识旨在制定意大利痴呆症护理管理的建议。鉴于阿尔茨海默病(AD)新的生物学定义和疾病修饰治疗(DMT)的可用性所引发的新情况,这项工作显得重要且及时。
意大利神经学会痴呆症指导委员会(SINdem)制定了适当的声明。邀请SINdem专家根据改良的三轮德尔菲法对声明进行投票。只有那些达到A级(完全同意≥75%)或B级(总体同意≥80%且完全不同意<5%)的声明才被纳入最终文件。使用科恩k值和组内相关系数对各轮答案的一致性进行分级。
46位专家对20项声明进行了投票,这些声明聚焦于以下方面:i)从早期诊断到晚期临床阶段管理的护理服务组织;ii)获取用于AD生物学诊断的生物标志物;iii)DMT给药所需的条件;iv)认知障碍患者管理的主要参与者和途径。在该过程结束时,4项声明(20%)获得了A级共识,而16项(80%)达到了B级共识。尽管这些回答反映了意大利各地区之间的异质性,但所有声明都有相当程度的一致性。
这种基于专家的德尔菲共识的高强度可能为改善认知功能下降个体从生物学诊断到DMT给药的就医过程提供指导,并可能为卫生系统提供有关痴呆症的提示。